Jiyoung Lee

Jiyoung Lee

Auto-generated profile, based on publicly available information

Jiyoung Lee

Hanyang University Institute for Rheumatology Research

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
SWSoyoung Won
Soyoung Won
SCSoo-Kyung Cho
Soo-Kyung Cho
DKDam Kim
Dam Kim
MHMINKYUNG HAN
MINKYUNG HAN
JLJiyoung Lee
Jiyoung Lee
SBSuk-Chul Bae
Suk-Chul Bae

5 July 2022 in Journal of Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
DPDae Jin Park
Dae Jin Park
YJYoung Bin Joo
Young Bin Joo
SBSo-Young Bang
So-Young Bang
JLJiyoung Lee
Jiyoung Lee
HLHye-Soon Lee
Hye-Soon Lee
SBSuk-Chul Bae
Suk-Chul Bae
Dae Jin Park, M.D., Young Bin Joo, M.D., Ph.D., So-Young Bang, M.D., Ph.D., Jiyoung Lee, M.S., Hye-Soon Lee, M.D., Ph.D., Sang-Cheol Bae, M.D., Ph.D., MPH. J Rheum Dis 2022;29:223-31. https://doi.org/10.4078/jrd.22.0006

15 December 2017 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
SCSoo-Kyung Cho
Soo-Kyung Cho
JLJiyoung Lee
Jiyoung Lee
MHMINKYUNG HAN
MINKYUNG HAN
SBSuk-Chul Bae
Suk-Chul Bae
YSYoon-Kyoung Sung
Yoon-Kyoung Sung
Treatment with disease-modifying anti-rheumatic drugs (DMARDs) has raised concerns about the risk of malignancies in rheumatoid arthritis (RA) patients. However, the association between biologic DMARDs (bDMARDs) and malignancy in previous reports remains controversial. Therefore we aimed to estimate the incidence of malignancy in early RA patients and to evaluate the relative risk of malignancy with use of bDMARDs. A retrospective cohort of incident RA patients was established using the Korean National Claims Database. Among a total of 14,081 RA patients identified, 1684 patients with a history of malignancy were excluded. We calculated the incidence rate of overall and individual malignancies. The standardized incidence ratio (SIR) of malignancies in bDMARD users was compared to that in nonusers. Multivariable logistic regression analysis was used to evaluate the impact of bDMARDs on the development of malignancies in early RA patients. A total of 12,397 early RA patients without a history of malignancy were enrolled. During 41,599 person-years (PY) of follow-up, 725 malignancies developed in 561 patients (174.3/10,000 PY) and 21 hematologic malignancies developed (5.0/10,000 PY). Patients treated with bDMARDs had a significantly lower incidence of overall malignancy compared to those not treated with bDMARDs (SIR 0.45 (95% CI 0.28–0.70)). However, this relationship was not significant with regard to hematologic malignancies (SIR 2.65 (95% CI 0.55–7.76)). On multivariable analysis, bDMARD use was a protective factor against the development of overall malignancy (odds ratio 0.42 (95% CI 0.25–0.73)). However, bDMARD use had no significant protective effect against the development of hematologic malignancies (odds ratio 1.69 (95% CI 0.38–7.59)). In early RA patients, bDMARD use decreases the overall risk of developing malignancies; however, it does not affect the risk of developing hematologic malignancies.

7 January 2026 in Lupus
Verified
Journal Article
Closed access
JSJUNGMIN SHIN
JUNGMIN SHIN
JLJiyoung Lee
Jiyoung Lee
HLHye-Soon Lee
Hye-Soon Lee
SBSo-Young Bang
So-Young Bang
SBSuk-Chul Bae
Suk-Chul Bae
Objective: Lupus nephritis (LN) is a major mortality risk factor in patients with systemic lupus erythematosus (SLE). We investigated the predictors of end-stage renal disease (ESRD) and mortality in patients with LN. Methods: We enrolled 599 Korean patients with biopsy-proven proliferative or membranous LN from a prospective cohort of 1497 patients with SLE. Baseline demographics, serology, histology, disease activity, and organ damage were collected and assessed. Regression models were used to evaluate predictors of renal survival and mortality. Results: We followed a total of 599 patients with proliferative LN (class III or IV/±V, N = 509) or membranous LN (class V, N = 90). Among these patients, 42 patients (7.0%) progressed to ESRD and 31 (5.2%) died. In a multivariate logistic regression analysis, antiphospholipid antibody positivity (OR 3.18, p = .023), higher activity and chronicity indices at biopsy (OR 1.14, p = .034; OR 1.33, p = .042), and sustained high disease activity (extra-renal adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2000 [SLEDAI-2K] ≥ 3, OR 4.33, p = .019) significantly influenced progression to ESRD after adjusting for age at LN diagnosis, gender, disease duration, and hypertension. While the 6-month renal response after induction treatment showed no association with ESRD risk, the 12-month treatment response demonstrated a significant association ( p < .001). Renal survival was poorer in patients with an activity index ≥6 and in those with a chronicity index ≥4 ( p = .013 and p = .002, respectively). Patients who developed ESRD had significantly worse overall survival than those who did not ( p = .028). Higher adjusted mean SLEDAI-2K (hazard ratio [HR] 1.43, p < .0001) and higher extra-renal adjusted mean SLEDAI-2K (HR 1.83, p < .0001) were significantly associated with increased overall mortality. Conclusions: Our study indicates that antiphospholipid antibodies, higher histologic activity and chronicity indices, and sustained high disease activity beyond renal items were independently associated with progression to ESRD. Mortality was increased among patients with ESRD and those with persistent high disease activity. These findings emphasize the need for stringent disease activity control and support clinicopathologic stratification to identify patients at high risk of adverse long-term renal outcomes.